News

August 7, 2018

T-cell immunotherapy research expands to more solid tumors

Seattle Children’s has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors.
July 20, 2018

Trial to assess feasibility, safety of CAR T-cell therapy for relapsed pediatric central nervous system tumors

A clinical trial is underway to examine the role of chimeric antigen receptor T-cell therapy for children and young adults with relapsed or refractory HER-2-positive central nervous system tumors.
June 19, 2018

Seattle Children’s Opens Immunotherapy Trial For Children With Relapsed Central Nervous System Tumors

Seattle Children’s has opened a pioneering chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory HER2-positive central nervous system (CNS) tumors where CAR T cells will be delivered directly into the brain.
March 28, 2018

The Top Doctors in Seattle for 2018

Health care is becoming increasingly complex—and remarkable. Research is unlocking more and more secrets about the human body, and conditions that were at one time hopeless have hopeful prognoses today thanks to new therapies.